Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
daNIS-3 phase II platform study in second-line metastatic colorectal cancer
jRCT2041210112Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of nisevokitug and tislelizumab in metastatic colorectal adenocarcinoma (mCRC) (6 arms), sponsored by Novartis. Primary endpoints: Dose-limiting toxicities in safety run-in and Progression-free survival (PFS). Started Mar 2022; status: completed.
02
Drugs
nisevokitugtislelizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2041210112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210112.